Based on these questions, we conducted a retrospective study to investigate the progression patterns, mechanisms of resistance, and subsequent therapeutic approaches for patients with ALK+ NSCLC in the era of second-generation ALK inhibitors. This evidence concerns the gene ALK and non-small cell lung carcinoma.